Photo Credit: LeventKonuk

The following is a summary of “Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series,” published in the March 2025 issue of BMC Ophthalmology by Bantounou et al. 

Researchers conducted a retrospective study to evaluate the efficacy and safety of faricimab in previously treated eyes with neovascular age-related macular degeneration (nAMD).  

They analyzed previously treated nAMD cases receiving at least 3 faricimab injections. Baseline data was obtained from February 2023 to September 2023, with follow-up until April 2024 and 2 cohorts were compared: (1) the “Loaded” cohort, receiving 4 weekly injections before treatment extension, and (2) the “Interval-Matched” cohort, continuing on prior treatment intervals. Efficacy was assessed by central subfield thickness (CST), macular fluid presence, and visual outcomes. Safety was evaluated based on adverse event (AEs) reports.  

The results showed that 237 individuals (297 eyes) were included, with a mean age of 80.7 ± 7 years, and 44% were males. A total of 2,237 faricimab injections were administered (7.5 ± 1.9 per eye). In the “Loaded” cohort, CST decreased from 315.1 ± 86.0 µm to 288.0 ± 63.6 µm (P < 0.001), dry macula increased from 11.0% to 42.5% (P < 0.001), vision improved from 67.9 ± 12.3 to 69.3 ± 13.4 letters (P= 0.002), and injection intervals extended from 5.3 ± 1.3 to 6.4 ± 2.1 weeks (P < 0.001). In the “Interval-Matched” cohort, CST declined from 302.8 ± 57.4 µm to 291.2 ± 62.6 µm (P= 0.001), dry macula increased from 22.5% to 47.7% (P < 0.001), vision remained stable at 65.9 ± 13.8 to 65.0 ± 17.1 letters (P = 0.613), and injection intervals extended from 6.6 ± 2.8 to 7.9 ± 3.2 weeks (P < 0.001). A total of 68 (28.7%) AEs were reported, including 9 (3.8%) serious cases.  

Investigators concluded that faricimab effectively improved anatomical outcomes and stabilized vision with fewer injections. Although a loading dose regimen resulted in superior outcomes, with more injections requirement.  

Source: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-025-03953-9